Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study.

摘要: To date, several small molecule inhibitors and monoclonal-antibodies (like ICR-62) have been used to treat tumors over-expressing epidermal growth factor receptor (EGFR). However, the limitations associated with these conventional applications accentuate necessity of alternative approaches. Mimotopes as compelling molecular tools could rationally be employed circumvent drawbacks. In present study, an M13 phage displaying ICR-62 binding peptide mimotope is exploited a vaccine candidate. It exhibited high affinity towards ICR62 polyclonal anti-P-BSA antibodies. Following mice immunization, phage-based induced humoral immunity. Elicited anti-EGFR antibodies were detected using ELISA method. Moreover, was tested on Lewis lung carcinoma model investigate prophylactic therapeutic effects. The tumor volume measured recorded in different animal groups evaluate anti-tumor effects vaccine. Our data indicate that reported potentially elicit specific resulting low titers EGFR-specific reduced growth. vivo experiments or vaccination showed no advantage. Furthermore, phage-mimotope might promising approach field cancer immunotherapy.